Figure 5. Dasatinib targets SRC and YES in LYN-negative lung ADC cells.

A. Cells were treated with dasatinib at 2 different concentrations (DMSO as control, IC₅₀ x 0.1, and IC₅₀), and pSFK levels were assessed by immunoblot using a cross-reactive pY416-SRC antibody. B. SFK tyrosine phosphorylation levels were quantified using ELISA in dasatinib-treated ADC cells. Cells were treated with dasatinib at 2 different concentrations (DMSO as control, and IC₅₀ x 0.1, and IC₅₀). The MFI values indicate phospho-Tyr SFK levels (n = 3; bars, SE; *, P < 0.05 vs. DMSO; ^#, P < 0.05 vs. IC₅₀ × 0.1).